Gene · 57007
Papers3,960
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,960
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ACKR3 in Skin Homeostasis, an Overlooked Player in the CXCR4/CXCL12 Axis. | J Invest Dermatol | 2025 | 39466217 | PubTator, text mining | PubMed |
| ACKR3 agonism induces heterodimerization with chemokine receptor CXCR4 and attenuates platelet function. | Eur J Clin Invest | 2025 | 39373210 | PubTator, text mining | PubMed |
| 5-Hydroxytryptamine G-Protein-Coupled Receptor Family Genes: Key Players in Cancer Prognosis, Immune Regulation, and Therapeutic Response. | Genes (Basel) | 2024 | 39766808 | PubTator, text mining | PubMed |
| Essential strategies for the detection of constitutive and ligand-dependent Gi-directed activity of 7TM receptors using bioluminescence resonance energy transfer. | bioRxiv | 2024 | 39713355 | PubTator, text mining | PubMed |
| Chemokine signaling in tumors: potential role of CXC chemokines and their receptors as glioblastoma therapeutic targets. | Expert Opin Ther Targets | 2024 | 39582130 | PubTator, text mining | PubMed |
| Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies. | bioRxiv | 2024 | 39574661 | PubTator, text mining | PubMed |
| Exosomes derived from M2 macrophages promote fibroblast autophagy to contribute to hypertrophic scar formation via CXCL2/CXCR7/mTOR pathway. | Hum Exp Toxicol | 2024 | 39557042 | PubTator, text mining | PubMed |
| Chemokine receptor CXCR7 antagonism ameliorates cardiac and renal fibrosis induced by mineralocorticoid excess. | Sci Rep | 2024 | 39505939 | PubTator, text mining | PubMed |
| Palladium(II)-Catalyzed Site-Selective C(sp3)-H Alkenylation of Oligopeptides. | Org Lett | 2024 | 39447064 | PubTator, text mining | PubMed |
| Hemin-induced platelet activation is regulated by the ACKR3 chemokine surface receptor and has implications for passivation of vulnerable atherosclerotic plaques. | FEBS J | 2024 | 39387619 | PubTator, text mining | PubMed |
| AI-assisted models to predict chemotherapy drugs modified with C60 fullerene derivatives. | Beilstein J Nanotechnol | 2024 | 39319207 | PubTator, text mining | PubMed |
| Heterogeneous expression of the atypical chemokine receptor ACKR3 in glioblastoma patient-derived tissue samples and cell cultures. | Sci Rep | 2024 | 39300240 | PubTator, text mining | PubMed |
| CXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients. | Antiviral Res | 2024 | 39265656 | PubTator, text mining | PubMed |
| Role of chemokine receptors in gastrointestinal mucosa. | Int Rev Cell Mol Biol | 2024 | 39260937 | PubTator, text mining | PubMed |
| Deficient GATA6-CXCR7 signaling leads to bicuspid aortic valve. | Dis Model Mech | 2024 | 39253784 | PubTator, text mining | PubMed |
| The SDF-1/CXCR4 axis is involved in adipose-derived stem cell migration. | Neurourol Urodyn | 2024 | 39149821 | PubTator, text mining | PubMed |
| Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy. | J Med Chem | 2024 | 39116445 | PubTator, text mining | PubMed |
| Bioactive Materials That Promote the Homing of Endogenous Mesenchymal Stem Cells to Improve Wound Healing. | Int J Nanomedicine | 2024 | 39099796 | PubTator, text mining | PubMed |
| Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites. | Eur J Med Chem | 2024 | 39053189 | PubTator, text mining | PubMed |
| Macrophage Migration Inhibitory Factor (MIF) Upregulates CXCR7 and Contributes to Chemotherapy Resistance in Colorectal Cancer. | Cell Biochem Biophys | 2024 | 39018005 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57007/papers?page=9